William K Ewing

US Patent:

7238670, Jul 3, 2007

Filed:

Oct 18, 2002

Appl. No.:

10/273975

Inventors:

Sesha Iyer Natarajan - Hillsborough NJ, US
Claudio Mapelli - Plainsboro NJ, US
Margarita M. Bastos - Plainsboro NJ, US
Michael Bernatowicz - Princeton NJ, US
Ving Lee - Hamilton NJ, US
William R. Ewing - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 38/08
C07K 7/04
A61K 38/00
A61K 38/02
A61K 38/16
C07K 2/00
C07K 7/08
C07K 1/00
C07K 1/14
C07K 1/107

US Classification:

514 17, 514 2, 514 13, 514 14, 514 15, 514 16, 530300, 530326, 530327, 530328, 530329, 530330, 530333, 530344, 530345

Abstract:

The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

US Patent:

7238671, Jul 3, 2007

Filed:

Apr 21, 2003

Appl. No.:

10/419399

Inventors:

Sesha Iyer Natarajan - Hillsborough NJ, US
Claudio Mapelli - Plainsboro NJ, US
Margarita M. Bastos - Plainsboro NJ, US
Michael Bernatowicz - Princeton NJ, US
Ving Lee - Hamilton NJ, US
William R. Ewing - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 38/08
C07K 7/04
A61K 38/00
A61K 38/02
A61K 38/16
C07K 2/00
C07K 7/08
C07K 1/00
C07K 1/14
C07K 1/107

US Classification:

514 17, 514 2, 514 13, 514 14, 514 15, 514 16, 530300, 530326, 530327, 530328, 530329, 530330, 530333, 530344, 530345

Abstract:

The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

US Patent:

7534763, May 19, 2009

Filed:

Nov 8, 2006

Appl. No.:

11/594531

Inventors:

Feng Qian - Hillsborough NJ, US
William R. Ewing - Yardley PA, US
Claudio Mapelli - Plainsboro NJ, US
Douglas James Riexinger - Flemington NJ, US
Ving G. Lee - Hamilton NJ, US
Richard B. Sulsky - West Trenton NJ, US
Yeheng Zhu - Stockton NJ, US
Tasir Shamsul Haque - Yardley PA, US
Rogelio L. Martinez - Monmouth Junction NJ, US
Vijay Naringrekar - Princeton NJ, US
Nina Ni - Kendall Park NJ, US
Lori S. Burton - Robbinsville NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 38/00
C07K 2/00

US Classification:

514 2, 530300

Abstract:

The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.

US Patent:

20070287670, Dec 13, 2007

Filed:

Apr 25, 2007

Appl. No.:

11/740031

Inventors:

Sesha Natarajan - Hillsborough NJ, US
Claudio Mapelli - Plainsboro NJ, US
Margarita Bastos - Plainsboro NJ, US
Michael Bernatowicz - Princeton NJ, US
Ving Lee - Hamilton NJ, US
William Ewing - Yardley PA, US

International Classification:

A61K 38/10
A61K 38/05
A61K 38/06
A61P 3/00
C07K 7/00
C07K 7/08
C07K 7/06
A61P 3/10
A61K 38/07
A61K 38/08

US Classification:

514015000, 514016000, 514017000, 530300000, 530328000, 530329000, 530330000, 530331000, 530333000

Abstract:

The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

US Patent:

20100022457, Jan 28, 2010

Filed:

Nov 8, 2006

Appl. No.:

12/227780

Inventors:

Feng Qian - Hillsborough NJ, US
William R. Ewing - Yardley PA, US
Claudio Mapelli - Plainsboro NJ, US
Douglas James Riexinger - Flemington NJ, US
Ving G. Lee - Hamilton NJ, US
Richard B. Sulsky - West Trenton NJ, US
Yeheng Zhu - Stockton NJ, US
Tasir Shamsul Haque - Yardley PA, US
Rogelio L. Martinez - Monmouth Junction NJ, US
Vijay Naringrekar - Princeton NJ, US
Nina Ni - Kendall Park NJ, US
Lori S. Burton - Robbinsville NJ, US

International Classification:

A61K 38/08

US Classification:

514 15

Abstract:

The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.

US Patent:

20100210552, Aug 19, 2010

Filed:

Apr 30, 2010

Appl. No.:

12/771096

Inventors:

Sesha Iyer Natarajan - Hillsborough NJ, US
Claudio Mapelli - Plainsboro NJ, US
Margarita M. Bastos - Plainsboro NJ, US
Michael Bernatowicz - Princeton NJ, US
Ving Lee - Hamilton NJ, US
William R. Ewing - Yardley PA, US

International Classification:

A61K 38/16
C07K 14/00
C07K 7/00
A61K 38/04
A61P 3/04
A61P 3/06
A61P 3/10
A61P 9/12

US Classification:

514 12, 530324, 530327, 514 15, 530328

Abstract:

The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.